Sung A Chang Department of Internal Medicine, Division of Cardiology, Sungkyunkwan University School of Medicine, Samsung Medical Center

Similar documents
Imaging in Ischemic Heart Disease: Role of Cardiac MRI

MR Assessment of Myocardial Viability

Rational use of imaging for viability evaluation

Current Guidelines for Diagnosis of AMI Chest pain ST change on EKG Cardiac Enzymes

Cardial MRI; Approaching the Level of Gold Standard for Viability Assessment

I have no financial disclosures

Coronary Revascularization in Patients witj Severe LV Dysfunction.: Is the concept of viability still viable?

What the Cardiologist needs to know from Medical Images

CASE from South Korea

Myocardial viability testing. What we knew and what is new

The role of Magnetic Resonance Imaging in the diagnosis of viability & Coronary Artery Disease

Evaluation of Myocardial Viability: What Have We Learned from STICH? Professor of Medicine David Geffen School of Medicine at UCLA. Heart Failure (HF)

Imaging Saves Lives: An Evidence-Based Choice of Modality Magnetic Resonance Imaging

Cardiac Stress MRI: Detection of Ischemia. Disclosures: Dobutamine Stress MR. April 28, 2018

Coronary interventions

Detection and Assessment of MI: Use of Imaging Methods. Robert O. Bonow, M.D.

Qualitative and Quantitative Assessment of Perfusion

Rotation: Imaging 2. Nuclear Cardiology (in Imaging 1 and 2)

Perfusion, Viability, Edema and Hemorrhage: How it Can (and Should) Change Clinical Practice. Rohan Dharmakumar, Ph.D.

The Value of Stress MRI in Evaluation of Myocardial Ischemia

Old and new insights into viability:perfusion and Perfusion Reserve

Coronary Revascularization for Severe LV Dysfunction Is s. Is the concept of viability testing still viable?

Disclosures. GETTING TO THE HEART OF THE MATTER WITH MULTIMODALITY CARDIAC IMAGING Organ Review Meeting 25 September. Overview

Imaging ischemic heart disease: role of SPECT and PET. Focus on Patients with Known CAD

Cardiac magnetic resonance imaging in rheumatoid arthritis: promising or misleading? Sophie Mavrogeni MD FESC

Assessment of Ischemia and Viability

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)

J. Schwitter, MD, FESC Section of Cardiology

1. LV function and remodeling. 2. Contribution of myocardial ischemia due to CAD, and

Assessment Of Myocardial Viability

Cardiac Viability Testing A Clinical Perspective Annual Cardiac Imaging Symposium. Lisa M Mielniczuk MD FRCPC University of Ottawa Heart Institute

A Light in the Dark: Cardiac MRI and Risk Mitigation. J. Ronald Mikolich MD Professor of Internal Medicine Northeast Ohio Medical University (NEOMED)

Use of Nuclear Cardiology in Myocardial Viability Assessment and Introduction to PET and PET/CT for Advanced Users

FFR Incorporating & Expanding it s use in Clinical Practice

Gated blood pool ventriculography: Is there still a role in myocardial viability?

Imaging and heart failure

Debate Should we use FFR? I will say NO.

Cardiac MRI: Cardiomyopathy

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

Current Indications for Cardiac MRI: What You See is What You Get?

Cardiology for the Practitioner Advanced Cardiac Imaging: Worth the pretty pictures?

Current and Future Imaging Trends in Risk Stratification for CAD

PET myocard perfusion & viability Riemer Slart

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Conflict of Interest Disclosure

Stable Angina: Indication for revascularization and best medical therapy

Cardiac Imaging. Kimberly Delcour, DO, FACC. Mahi Ashwath, MD, FACC, FASE. Director, Cardiac CT. Director, Cardiac MRI

MRI ACS-ben. Tamás Simor MD, PhD, Med Hab. University of Pécs, Heart Institute

ESC CONGRESS 2010 Stockholm, august 28 september 1, 2010

CMR stress Perfusion: what's new?

Acute chest pain: game changer or waste of resources? CMR one stop shop for function, structure and perfusion

2019 Qualified Clinical Data Registry (QCDR) Performance Measures

EAE Teaching Course. Magnetic Resonance Imaging. Competitive or Complementary? Sofia, Bulgaria, 5-7 April F.E. Rademakers

Outils d évaluation myocardique par relaxométrie (Myomaps)

Radiologic Assessment of Myocardial Viability

Stress MRI is here to stay. Professor James Moon Barts Heart Centre UCL Director of Imaging

Validation of CT Perfusion Imaging Against Invasive Angiography and FFR on a 320-MDCT Scanner

Viability Testing Using Dynamic Echocardiography

The best from Euro-Echo Ischemic heart disease. Fausto Rigo,FESC Department of Cardiology Mestre-Venezia Hospital,Italy

Cardiac Imaging Tests

Pearls & Pitfalls in nuclear cardiology

Typical chest pain with normal ECG

Corrective Surgery in Severe Heart Failure. Jon Enlow, D.O., FACS Cardiothoracic Surgeon Riverside Methodist Hospital, Ohiohealth Columbus, Ohio

Imaging of the Heart Todd Tessendorf MD FACC

Imaging congestive heart failure: role of coronary computed tomography angiography (CCTA)

Revascularization Strategies in Patients with Severe LV Dysfunction

Imaging of Coronary Artery Disease: II

Mechanisms and role of contrast echocardiography

CT for Myocardial Characterization of Cardiomyopathy. Byoung Wook Choi, Yonsei University Severance Hospital, Seoul, Korea

NUCLEAR CARDIOLOGY UPDATE

Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies

Revascularization In HFrEF: Are We Close To The Truth. Ali Almasood

CARDIAC MRI. Cardiovascular Disease. Cardiovascular Disease. Cardiovascular Disease. Overview

@02-126_Coronary_calcification.ppt. Professor Molecular and Medical Pharmacology

CLINICAL CONSEQUENCES OF THE

Myocardial Stress Perfusion Imaging using CMR

FFR in Multivessel Disease

State of the Art. Advances in Cardiovascular Imaging. ESC Congres Stockholm September 1, 2010 Frank E. Rademakers, MD, PhD, FESC

MRI Assessment of the Right Ventricle and Pulmonary Blood Flow, Perfusion and Ventilation

Benefit of Performing PCI Based on FFR

The use of Cardiac CT and MRI in Clinical Practice

ADVANCED CARDIOVASCULAR IMAGING. Medical Knowledge. Goals and Objectives PF EF MF LF Aspirational

Fulfilling the Promise

Management of High-Risk CAD : Surgeons Perspective

What s New in Cardiac MRI

SPECT or PET for Cardiovascular Screening in High-Risk Patients

Advanced Imaging MRI and CTA

Maria Angela S. Cruz-Anacleto, MD

Fractional Flow Reserve from Coronary CT Angiography (and some neat CT images)

Microvascular Disease: How to Diagnose and What s its Treatment

CHRONIC CAD DIAGNOSIS

Original Research. Li-Yueh Hsu, DSc, W. Patricia Ingkanisorn, MD, Peter Kellman, PhD, Anthony H. Aletras, PhD, and Andrew E.

Fractional Flow Reserve: Review of the latest data

Can SCMR CMR protocol recommendations

DIAGNOSTIC TESTING IN PATIENTS WITH STABLE CHEST PAIN

SPECT TRACERS Tl-201, Tc-99m Sestamibi, Tc-99m Tetrofosmin

Le FDG dans l évaluation de la viabilité : Quelle place par rapport aux autres traceurs?

PET for the Evaluation of Myocardial Viability

Management of stable CAD FFR guided therapy: the new gold standard

Cardiac MR Cardiac CT

Transcription:

CMR Perfusion and Viability A STICH Out of Time? Sung A Chang Department of Internal Medicine, Division of Cardiology, Sungkyunkwan University School of Medicine, Samsung Medical Center

Can Imaging Improve Patient s Outcome?

Myocardial viability in ischemic heart disease Myocardial Viability dysfunctional myocardium subtended by diseased coronary arteries with limited or absent scarring that therefore has the potential for functional recovery

Myocardial Viability and Survival in patients with CAD and Severe LV Dysfunction Group I: Viability(+) and revascularization GroupII: Viability(+) and medical Tx GroupIII: Viability(-) and revascularization GroupIV: Viability(-) and medical Tx AFRIDI I et al. J Am Coll Cardiol 1998;32:921 6

Myocardial Viability Testing and Impact of Revascularization Meta analysis of 3088 patients (DSE/SPECT/ PET) Allman et al. JACC Vol. 39, No. 7, 2002

All-Cause Mortality As Randomized HR 0.86 (0.72, 1.04) P = 0.123 0.46 0.41 N Engl J Med 2011;364:1607-16

Cardiovascular Mortality As Randomized HR 0.81 (0.66, 1.00) P = 0.050 Adjusted HR 0.77 (0.62, 0.94) Adjusted P = 0.012 0.39 0.32 N Engl J Med 2011;364:1607-16

STICH substudy N Engl J Med 2011;364:1617-25

K-M analysis of the probability of death P=0.21 after adjusting for baseline variables N Engl J Med 2011;364:1617-25

K-M analysis of CV mortality P=0.21 after adjusting for baseline variables N Engl J Med 2011;364:1617-25

Viability Testing for Myocardium?

Cardiac Imaging for Viability Echo Nuclear test Cardiac MR Cardiac CT

by SPECT or dobutamine echo N Engl J Med 2011;364:1617-25

Limitations of the STICH viability substudy Lack of randomization in viability substudy Optional viability testing performed at clinician s discretion Only about one-half of eligible patients from the main trial Significant differences in baseline characteristics between those with versus those without viability testing. Acceptable viability tests do NOT have highest sensitivity or negative predictive value for identifying viable myocardium JACC CV Imaging 2012;5:550-558

Some cardiologists say.. Results might be different if they used other imaging modality like CMR!

Viability imaging tests Nuclear scan Dobutamine/exercise stress Which test is preferred? DE-MRI

CMR assessment of viability ; DE-CMR Fibrosis Imaging Area of delayed hyperenhancement = nonviable myocardium (Bright is dead!) Kim RJ et al, Circulation 1999

Delayed Enhancement CMR Physiological basis

CMR assessment of viability ; DE-CMR 1-25% DE Left: 26-50% DE Right: 51-75% DE 76-100% DE Kim RJ et.al., J Cardiovasc Magn Reson

CMR assessment of viability ; DE-CMR Kim RJ et.al. N Engl J Med 2000 Viability (%) 100 80 60 40 20 0 0% 1-25% 26-50% 51-75% 76-100% Delayed enhancement

CMR

DE - CMR

After CABG

After CABG

Advantages of CMR Higher spatial resolution as compared with SPECT 42 year-old male with NSTEMI Perfusion defect (-)

A Wagner, R Judd, R Kim et al. Lancet 2003:361:374- Advantages of CMR Direct visualization of nonviable tissue

Strong images in small or shallow lesions A Wagner, R Judd, R Kim et al. Lancet 2003:361:374-

Comparison with SPECT in Three-vessel Diseases Chung and Choi, AJR 2011

Segmental scar score 0 = absence of DHE 1 = DHE of 1% to 25% of LV segment 2 = DHE extending to 26% to 50% 3 = DHE extending to 51% to 75% 4 = DHE extending to 76% to 100%

Kaplan-Meier Curves Demonstrating Difference in Outcomes Among 4 Quartiles automatically derived scar: >2SD above viable myocardium Deborah H Kwon et al. JACC : Cardiovascular Imaging 2009;2;1

Kaplan-Meier Curves Demonstrating Difference in Outcomes Among 4 Quartiles Total scar score : summed segmental scar scores/patient divided by 17 DeborahH Kwon et al. JACC : Cardiovascular Imaging 2009;2;1

Adenosine Stress Perfusion CMR First pass perfusion CMR Infarcted Myocardium Contrast injection Normal Myocardium Ischemic Myocardium < 1 min > 10 min First-Pass perfusion Time-intensity curve at normal and pathologic myocardium after administration of contrast media. time

Adenosine 3-4 minutes TIME [minutes] 0 5 13 16 contrast injection 17 25 32 contrast injection 33 38 45 CMR TECHNIQUE CINE MORPHOLOGY STRESS PERFUSION ADDITIONAL IMAGING REST PERFUSION 5 minute delay DELAYED ENHANCEMENT COMMENTS Includes - Cardiac function, volumes, mass - Valvular morphology, stenosis, regurgitation - Pericardium Optional - Dark and bright blood tomographic imaging of heart & great vessels - T2 weighted imaging (or T1 or T2 mapping) of acute injury Performed in appropriate patients - Post MI risk stratification - Ischemia evaluation 15 min interval between stress/rest perfusion - Velocity/Flow imaging for valvular disease and cardiac output - Whole heart coronary MRA (may be performed prior to contrast) - Additional cine imaging Performed in appropriate patients - Improves specificity of stress perfusion imaging - Quantification of myocardial blood flow reserve Typical Sequence - 2D or 3D, Segmented (high resolution and high SNR) Useful Additional Sequences - Single Shot (rapid, no breath hold required, resistant to arrhythmias) - Long inversion time (~600 ms) (useful for thrombus detection and no-reflow regions in acute MI) - Post contrast T1 mapping for ECV measurement and serial quantification

Adenosine Stress Perfusion Protocol (SMC protocol) 0 4 8 12 16 20 24min Adenosine 140μg/Kg 5-6min Gd-DTPA 0.1mmol/Kg Gd-DTPA 0.1mmol/Kg Cine MRI Stress perfusion Flow Coronary MRA Rest Perfusion Delayed enhancement

Perfusion MRI

Scanning protocol and Interpretation of CMR Assessment of wall motion abnormality Adenosine Stress Perfusion image Viability image (visualization of dead tissue)

a. Interpretation Algorithm b. Examples START DE-CMR Stress Perfusion Rest Perfusion Coronary Angiography DE-MRI + Patient 1: 70% stenosis in LCX marginal artery CAD Stress Perfusion + Reversible defect Rest Perfusion Matched defect No CAD Patient 2: proximal 95% stenosis in LAD artery CAD No CAD Patient 3: Normal coronary arteries

Sensitivity MR-IMPACT 18-center multivendor study N = 234 Comparison of Perfusion MR with SPECT and CAG All Patients (1-3vessel Ds) Multi-vessel disease Comparison vs multi-center single-vendor study 1-Specificity 1-Specificity 1-Specificity Schwitter, EHJ 2008

Lancet 2012; 379: 453 60

Flow-Independent Dark-blood DeLayed Enhancement technique (FIDDLE) SCMR 2016 presented, from DCMRC

Flow-Independent Dark-blood DeLayed Enhancement technique (FIDDLE) SCMR 2016 presented, from DCMRC

SCMR 2016 presented, from DCMRC

CMR is the only cardiac imaging to visualize the viable and non-viable myocardium. Resolution of CMR stress imaging and viability imaging is better than nuclear imaging. CMR is not a single image - interpretation of CMR is more integrated and summation of multiple imaging technique. Viability imaging in CMR is progressing.